The impact of COVID-19 vaccination on patients with congenital heart disease in England: a case-control study
Authors' conclusion
We observed a lower absolute risk of hospitalisation and death from COVID-19 in CHD patients after vaccination. However, in vaccinated CHD patients, an elevated risk of severe outcomes persists compared with vaccinated people without CHD.
Study context
- Population
- Patients with congenital heart disease and matched controls with first-recorded SARS-CoV-2 infection, England
- Participants
- 57,550 / 225,160 / 7,805 / 27,620
- Comparison
- Patients with congenital heart disease (CHD) vs matched controls, before and after COVID-19 vaccination
- Vaccinated CHDn = 57,550
- Vaccinated controlsn = 225,160reference
- Unvaccinated CHDn = 7,805
- Prevaccination controlsn = 27,620
- Outcome
- Severe COVID-19 outcomes:
- COVID-19-related hospitalisation
- Death
Methodological detailsmatched (age, sex, ethnicity, GP practice), linked English electronic health records
- Matched (age, sex, ethnicity, GP practice)
- Linked English electronic health records
Main finding
As reported in the abstract
Vaccinated CHD
- Hospitalisation
- 0.5%
- Death
- 0.5%
Vaccinated controls
- Hospitalisation
- 0.2%
- Death
- 0.3%
Hospitalisation
Vaccinated CHD0.5%
Vaccinated controls0.2%
Death
Vaccinated CHD0.5%
Vaccinated controls0.3%
Vaccinated CHD vs Vaccinated controlsAdjusted odds ratio (CI)P value
Hospitalisation
2.24(1.88–2.65)
P < 0.001Death
1.81(1.54–2.13)
P < 0.001Observational data: associations, not effects.
Further findings
| Outcome | Prevaccination controls |
|---|---|
| COVID-19-related hospitalisation and mortality, post-vaccination vs prevaccination CHD | |
| Hospitalisation | 15.8% |
| Mortality | 4.6% |
- COVID-19-related hospitalisation and mortality, post-vaccination vs prevaccination CHD: Post-vaccination CHD Hospitalisation 0.5% · Mortality 0.5%
Waning of vaccine efficacy; myocarditis, pericarditis or thrombotic events
- No evidence that vaccine efficacy declined faster in CHD, or of a larger increase in myocarditis, pericarditis or thrombotic events
Safety
Vaccine-associated myocarditis, pericarditis or thrombotic events
- No evidence of a larger increase in incidence in patients with CHD
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The impact of COVID-19 vaccination on patients with congenital heart disease in England: a case-control study. Heart. Published 11 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →